The versatility of oligonucleotides as potential therapeutics (Q36897394)

16 August 2017

1 reference

title

The versatility of oligonucleotides as potential therapeutics (English)

1 reference

16 August 2017

Fritz Eckstein

1

1 reference

PubMed ID

17665991

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

7

1 reference

16 August 2017

1021-1034

1 reference

Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Inhibition of MDR1 expression with altritol-modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

High potency silencing by single-stranded boranophosphate siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Morpholino antisense oligomers: the case for an RNase H-independent structural type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

RNase H-independent antisense activity of oligonucleotide N3 '--> P5 ' phosphoramidates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Perspective: machines for RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Control of translation and mRNA degradation by miRNAs and siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Assembly and function of RNA silencing complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

RNA interference and chemically modified small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Progress towards in vivo use of siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

The silent treatment: siRNAs as small molecule drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

RNAi therapeutics: a potential new class of pharmaceutical drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Strategies for silencing human disease using RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Interfering with disease: a progress report on siRNA-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

RNAi-mediated gene silencing in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Inhibition of respiratory viruses by nasally administered siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

A single siRNA suppresses fatal encephalitis induced by two different flaviviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Protection against lethal influenza virus challenge by RNA interference in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

siRNA-mediated off-target gene silencing triggered by a 7 nt complementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

On the art of identifying effective and specific siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

5'-Triphosphate RNA is the ligand for RIG-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Aptamer mediated siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Strategies to determine the biological function of microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Silencing of microRNAs in vivo with 'antagomirs'

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Improved targeting of miRNA with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

The structural basis of ribosome activity in peptide bond synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

A genomewide search for ribozymes reveals an HDV-like sequence in the human CPEB3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

A DNA enzyme that cleaves RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

DNAzymes: from creation in vitro to application in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

DNA-based therapeutics and DNA delivery systems: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Gaining target access for deoxyribozymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Aptamers as tools for target validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Aptamer therapeutics advance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Gene therapy progress and prospects: RNA aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

RNA aptamers as reversible antagonists of coagulation factor IXa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

An L-RNA-based aquaretic agent that inhibits vasopressin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Transcription factor decoys: a new model for disease intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

Chemical modifications to improve the cellular uptake of oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

On the in vitro and in vivo Properties of Four Locked Nucleic Acid Nucleotides Incorporated into an Anti-H-Ras Antisense Oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.1021

10.1517/14712598.7.7.1021

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17665991